• White Facebook Icon
  • White Twitter Icon
  • White YouTube Icon
  • White Instagram Icon
GRADIENT_ IMPACT Banner SELECT Revised A

IMPACT is investigating how the virus affects the immune system and how people with risks for blood cancer may respond to COVID-19 and its emerging vaccines. 

The IMPACT study is an affiliate study of the PROMISE and PCROWD Studies. We will analyze blood samples for up to one year to learn how COVID-19 exposure affects the immune system. All participants enrolled in IMPACT will receive a free antibody test to determine if they have been exposed to the virus that causes COVID-19.

How to Enroll and Get Antibody Testing

 Log in to your study dashboard
   Opt-In to the IMPACT study

 Get tested for COVID-19 antibodies

      Already enrolled? PROMISE Dashboard Login / PCROWD Dashboard Login

      Not enrolled? Both studies are welcoming new participants.

PROMISE Study Logo - Dana-Farber

1. Join as a PROMISE Study participant
The PROMISE Study is for healthy people with risks for multiple myeloma but who do not have the early warning signs (called precursor conditions.)
Who can join? 

  • Black or African American Individuals age 40 - 75 years

       – And / Or –

  • Close family members of anyone with multiple myeloma OR or a precursor condition, also 40 - 75 years of age.

Close family members are people of any race who have a parent, sibling, or child with: 

      Multiple myeloma OR one these related conditions: 

2. Join as a PCROWD Study participant
For anyone, age 18+, who has been diagnosed with a precursor condition for multiple myeloma.

Who can join IMPACT Study
How do I join IMPACT Study

ABOUT THIS STUDY

  • We study how the immune system responds to COVID-19 and the long-term impact of the virus in patients with precursor conditions and healthy individuals. The goals of IMPACT are:

 

  • To compare COVID-19 antibody levels and immune cell changes in patients with precursor conditions to those without precursor conditions.

  • To identify the people most at risk for long-term symptoms and immune complications after infection to COVID-19.

THE IMPORTANCE

The coronavirus disease, called COVID-19, continues to have a serious impact on millions of people, including people with or at risk for cancer. It is important to learn how COVID-19 will impact people with risks for blood cancer.

We Seek to Learn Answers to Questions Like These:

  • Do people who have risks for blood cancer also have greater risks for COVID-19?

  • If so, is there a COVID-19 treatment that would help people with cancer risks to protect their long-term health? 

  • Who is most at risk for long-term symptoms and immune complications after infection with COVID-19?

  • Will precursor conditions make future COVID-19 vaccines more or less effective?

  • Do precursor patients who have recovered from COVID-19 have COVID-19 antibodies?

  • Are these patients who have recovered from COVID-19 protected from re-infection?  If so, for how long?

IMPACT Study Banner-04.png
 

How does the IMPACT Study work?

1. Sign Up

Enroll in the PROMISE STUDY or PCROWD STUDY.

Then opt in for the IMPACT STUDY

2. Take COVID-19 Antibody Test

  1. A test kit will be mailed to your home. 

  2. Take the kit to one of the 2,200 Quest Diagnostics labs in the U.S. and provide a blood sample.

  3. The lab will screen for COVID-19 antibodies using the Abbott Laboratories Inc. test kit (also called SARS-CoV-2 IgG Immunoassay.)

3. Get Results

  • Participants will receive the initial COVID-19 antibody test results from Quest Diagnostics by email. 

  • Participants will be asked to submit additional blood samples at 3 months, 6 months, and 12 months using a follow-up test kit that we will send to you.

  • The test results from these follow-up samples will be used only for research and will not be returned to individual participants.

4. Study Samples and Share Learnings

  • After you receive the results of your COVID-19 Antibody Test, we will perform additional tests to examine your immune cells.  

  • Although we are not sharing reports about any individual's immune cell data, we will share combined group data for all patients every few months. You can learn more about risks for different groups and use the information to make more informed decisions.

  • Thank you for your interest in helping to move research forward!

Dana-Farber Cancer Institute logo

© 2020 Dana-Farber Cancer Institute, Boston MA | United States |  Terms of Use  |   Privacy Policy